New Antibody Stops Aggressive Breast Cancer
Researchers developed a targeted antibody against SFRP2 that disrupts survival mechanisms of triple-negative breast cancer, reprograms immune cells to fight the tumor, and shows promise in preclinical models, including resistant and metastatic cases, paving the way for potential new treatments.